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ABSTRACT
Background
Rosemary leaves powder has been reported to reduce in a dose-dependent manner, glucose levels, lipid 
profile and lipid peroxidation in humans. However, patients should ingest high doses of powder contained 
in capsules. This formulation constitutes the intake of 10 capsules per day, so the active metabolite must 
first, be released and then absorbed (for which, rosemary leaf powder must be mixed with gastric juice).
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Diabetes mellitus type 2 (T2D) is considered a 
serious public health problem due to the high 
increase in incidence and prevalence.1 The main 
clinical feature of T2D is hyperglycemia, which 
results from defects in insulin secretion, cellular 
resistance to the action of insulin, or both, creating 
an inflammatory alteration of pancreatic β cells or 
a resistance to the action of insulin in different tis-
sues.2 Indeed, this autoimmune chronic disease is a 
leading cause of blindness, renal failure, myocar-
dial infarction, stroke, and the amputation of lower 
limbs.3,4 Current therapy is set for each patient 
according to their economical budget.5–7 The most 
accepted therapy is based on pharmacological 
drugs, which include oral hypoglycemic drugs (e.g., 
sulfonylureas, meglitinides, biguanides, thiazoli-
dinediones, acarbose, and miglitol). Insulin ther-
apy is used in case of drug therapy failure.8 In other 
cases, T2D patients select “alternative therapies” 
such as medicinal plants. However, it has been 
observed that medicinal plants or their extracts can 
optimize glucose metabolism and the integral con-
dition of T2D patients, not only by their 
hypoglycemic effects but also by improving their 
lipid profile, antioxidant status, and capillary func-
tion.9,10 One example of these medicinal plants is 
Rosmarinus officinalis, known as rosemary, which 
has been used for diabetes treatment. Although 
this plant is native from the Mediterranean Basin, 
it has a worldwide distribution. The properties of 
this plant reside in the richness of active principles 
that have an effect on almost all organs of the 
human body.11,12 Moreover, it is a rich source of 
phenolic phytochemicals having significant 
 antioxidant, anti-inflammatory, hypoglycemic, 
 hypolipidemic, hypotensive, anti-atherosclerotic, 
antithrombotic, hepatoprotective, and hypocholes-
terolemic effects.13 In vivo studies have shown that 
rosemary reduces glucose levels in rabbits and rats 
with induced diabetes.14–17 According to the litera-
ture, it has been demonstrated that doses of 2, 5, 
and 10 g/day of rosemary leaves powder reduce in 
a dose-dependent manner glucose levels, lipid pro-
file, and lipid peroxidation in randomly selected 
human participants.18 In an independent study, it 
has been reported that the intake of 3 g/day of 
Aim
Evaluate whether a shortened dose and time of treatment as well as the pharmaceutical presentation in 
rosemary tea (Rosmarinus officinalis) instead of powder have a therapeutic effect in the treatment of 
T2D.
Method
The complementary therapy with Rosemary tea (2g/1 litre of water per day) were evaluate on resistance 
to insulin, oxidative stress, biochemical parameters and anthropometric measurements in forty patients 
T2D under treatment with metformin and/or glibenclamide afther  giving your authorization through 
informed consent.
Results
The data indicated that Rosemary tea intake after 90 days, statistically decreased (p < 0.05) anthropo-
metric parameters like the body mass index and waist-hip ratio. Remarkably, this treatment decreased 
the percentages of glycated hemoglobin, insulin resistance, and the pancreatic β-cell function and lastly, 
a significant difference in lipid peroxide levels was found.
Conclusion
These data show that shortening time and dose, as well as changing the formulation of the Rosemary 
plant constitutes a promising treatment for drug-resistant T2D patients.
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powder for 4 weeks reduces in 9% fasting blood 
glucose and generates favorable changes in lipid 
profiles.19 However, this formulation constitutes 
the intake of 10 capsules per day, representing a 
disadvantage for patients due to the amount that 
they have to take in order to have a therapeutic 
effect. Therefore, in the present work, we sought to 
investigate whether by shortening the dose, time of 
treatment, as well as changing the pharmaceutical 
presentation of the Rosemary plant, a therapeutic 
effect in T2D could be observed.
MATERIAL AND METHODS
Population of Study
We studied 40 patients diagnosed with T2D, of 
which 67.5% were female and 13 (32.5%) were 
male. The mean age of the patients was 56.3 ± 9.97 
years. The study group included 45% of the patients 
under pharmacological treatment with metformin, 
17.5% with glibenclamide, and 37.5% with met-
formin and glibenclamide. From the total number 
of patients, 70% reported having a first-line genetic 
load for diabetes and 27.5% of the patients were 
known to have dyslipidemia. In addition, each 
patient underwent a clinical history, with emphasis 
on the development of diabetes, time of evolution, 
detection method, type of diet, and physical activ-
ity. All patients received an alternative therapy with 
rosemary tea in a dose of 2 g/L/day.
The participants gave their informed written 
consent. The research was carried out in accor-
dance with the Declaration of Helsinki and it was 
approved by the Research and Ethics Committee 
of the “Hospital General 450” (registration No. 
023), by the Ministry of Health of the state of 
Durango, and by the state´s Bioethics Committee 
(registration No. 003/CEB 15), belonging to the 
Ministry of Health of the state of Zacatecas.
Preparation of Rosemary Tea
Each patient was provided with a box contain-
ing 30 sachets of rosemary leaves (2 g each). The 
rosemary leaves employed were acquired in 
Plantas Medicinales de América, S.A. de C.V. 
México, D.F., and then, packed and shipped to 
the laboratory of ethnopharmacology at the 
Autonomous University of Zacatecas, according 
to the Official Mexican Norm NOM-072-
SSA1-1993. The patients were instructed to add a 
bag in a liter of boiling water (boiled for 3 min) 
and then pass through a sieve to remove the rose-
mary leaves. The patients were instructed to con-
sume it as drinking water during the day.
Anthropometric Measures
Weight was measured using an electronic digi-
tal scale with a capacity of 130 kg. Height was 
measured using a stadiometer with a length of 2 
m, divided into centimeters and subdivided into 
millimeters.
Waist circumference was measured in the hor-
izontal plane midway in the distance of the supe-
rior iliac crest and the lower margin of the last 
rib, under the clothes, and at the end of a normal 
exhalation, using a flexible and inelastic measur-
ing tape. The hip was measured at the greatest 
circumference of the gluteal region.
All measurements were made before initiating 
phytopharmacological therapy (basal value) and 
at 90 days of the therapy.
Blood Samples
The blood sample was obtained by venipunc-
ture in the flexor zone of the elbow before the 
intake of rosemary tea (baseline sample) and at 
90 days of phytopharmacological therapy.
Biochemical Testing Measurements
Biochemical profile analyses were performed 
at the Biomedical Research Diabetes Clinic 
belonging to the Ministry of Health of Durango. 
The measurements were made by enzymatic 
methods. Quantification of insulin was carried 
out through the enzyme immunosorbent assay 
for the quantitative detection of antibodies 
anti-insulin (MexLab®).
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Determination of Lipid Peroxides
Malondialdehyde (MDA) concentrations were 
measured as thiobarbituric acid reactive substances 
(TBARS) according to a modified version of the 
procedure described by Yagi.20 In brief, 0.3 mL 
serum was mixed with 2 mL 1/12 NH2SO4 in a cen-
trifuge tube and gently shaken. Then, 0.3 mL of 
10% phosphotungstic acid was added to the tube in 
addition to 1 mL of thiobarbituric acid (0.6%). The 
tube was then heated in a boiling water bath for 1 h. 
The samples were cooled to room temperature. The 
resulting chromogen was extracted with 1.3 mL 
n-butyl alcohol by vigorous shaking. The organic 
phase was separated by centrifugation at 1600 × g 
for 10 min, and its absorbance was recorded at a 
wavelength of 530 nm. The level of absorbance was 
converted intro nmol/mL MDA from a standard 
curve generated with 1,1,3,3-tetraethoxypropane 
(Sigma Chemical, St. Louis, MO).
Homeostatic Model Assessment
The insulin resistance score (Homeostasis 
Model Assessment [HOMA]) was calculated with 
the formula: fasting serum insulin (µU/mL) and 
fasting plasma glucose (mmol/L)/22.5, as 
described by Matthews et al.21
Statistical Analysis
The results are presented as mean ± standard 
deviation. The comparisons among baseline value 
(before starting the alternative therapy) and 90 days 
of therapy with rosemary tea were made with the 
Wilcoxon and/or paired t-test. Comparisons for cat-
egorical variables were performed using chi-squared 
and/or Fisher’s exact test. A Pearson’s correlation 
analysis was performed to test the relationship 
between biochemical indicators and insulin resis-
tance, weight, body mass index (BMI), and waist to 
hip ratio. All tests were performed using the statisti-
cal program SPSS v.20, Chicago, IL; P-values <0.05 
were considered statistically significant.
Data Availability Statement
The data types used to support the findings of this 
study are included within the article and are restricted 
by the Research and Ethics Committee of the 
“Hospital General 450” (Secretary of Health of the 
state of Durango, Mexico) to protect patient privacy. 
Data are available from the corresponding author, 
Dr Lazalde Ramos, Campus UAZ Siglo XXI, Edif. 
L1, 3er piso, Carretera Zacatecas-Guadalajara Km 
6, Ejido la Escondida, 98160 Zacatecas, México. 
Phone: (+52) (492) 1702977, email address; blancala-
zalde@gmail.com), for researchers who meet the cri-
teria for access to confidential data.
RESULTS
Rosemary Tea Intake Reduced the Anthropometric 
Measurements of T2D Patients
To gain further insight into the study of the 
potential of the phytopharmacological treatment 
of T2D disease based on rosemary tea intake, Table 
1 shows the anthropometric measurements (weight, 
BMI, waist, and/or hip) from the T2D patients’ 
post-therapy with rosemary tea; weight and BMI 
did not decrease significantly. In contrast, waist and 
hip (6.07–5.57%) decreased significantly (P < 0.000) 
at 90 days post-intake of rosemary tea.
Rosemary Tea Ingestion Reduced Glucose and 
Insulin Resistance
Next, since one of the major concerns in T2D 
includes glucose levels and insulin resistance, the 
effect of the ingestion of rosemary tea on these 
parameters was investigated. From Table 1, it is 
evident that there is a decrease in the percentage 
of glycosylated hemoglobin (9.09–7.72%) and in 
the insulin resistance (2.29–1.12 mU/mL) (P < 
0.000) and also in the pancreas with values for 
β-cell functionality (54.06–39.59%) (P < 0.003). 
Therefore, there was an increase in the percentage 
of insulin sensitivity (48.66–98.48%) (P < 0.000) 
in T2D patients (Table 1).
No Effect Was Observed in the Lipid Profile of T2D 
Patients after rosemary Tea Ingestion; however, It 
Did Decrease Lipid Peroxidation
Previous data from the literature have shown 
that the intake of 3 g of rosemary powder during 
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4 weeks generates favorable lipid profiles.19 
Therefore, cholesterol, triglycerides, high, and 
low lipoproteins were determined in the blood of 
the T2D patients. Interestingly, under the rose-
mary tea formulation, no significant differences 
were found while comparing the basal value with 
respect to the values obtained 90 days post-intake 
of rosemary tea (Table 2). However, rosemary tea 
intake significantly decreased MDA levels in 30 
days from 0.789 ± 0.364 to 0.375 ± 0.306 nM/mL, 
while maintaining this decrease in relation to 
time, in 60 days (0.344 ± 0.238) and in 90 days 
(0.365 ± 0.176 nM/mL) (Figure 1).
In the Table 3 shows the comparison by 
Fisher’s exact test of the percentage of patients 
at  high risk of diabetic complications before 
 consuming rosemary tea and 90 days post- 
consumption. The number of patients with tri-
glyceride values >150 mg/dL decreased by 15.62% 
and the number of patients with Low-Density 
Lipoprotein Cholestero c-LDL>100 mg/dL 
decreased by 7.14%.
TABLE 1. Anthropometric and Index Homeostasis Model Assessment (HOMA) Values of T2D 
Patients before and after Intake of Rosemary Tea
Before Therapy with 
Rosemary Tea 
(X̄ ± SD)
At 90 Days Post-Intake 






Weight (kg) 74.43 ± 14.24 73.46 ± 14.71 ↓ 1.30 NS
Body mass index (kg/m2) 27.54 ± 4.40 27.19 ± 4.41 ↓ 1.27 NS
Waist (cm) 91.38 ± 9.71 85.83 ± 9.64 ↓ 6.07 0.000
Hip (cm) 103.52 ± 10.72 97.75 ± 7.94 ↓ 5.57 0.000
Waist-to-hip ratio 0.886 ± 0.058 0.879 ± 0.060 ↓ 0.79 NS
Glucose (mg/dL) 181.18 ± 80.75 162.96 ±72.89 ↓ 10.05 NS
HbA1c(%) 9.09 ± 2.72 7.72 ± 1.82 ↓ 15.07 0.000
Insulin resistance (mUI/mL) 2.29 ± 0.98 1.12 ± 0.75 ↓ 51.09 0.000
Insulin sensitivity (%) 48.66 ± 12.47 98.48 ± 20.21 ↑ 102.38 0.000
Β-cell function (%) 54.06 ± 30.45 39.50 ± 29.95 ↓ 26.93 0.003
The comparisons among baseline values (before starting the alternative therapy) and 90 days of therapy with rosemary tea were performed 
with the Wilcoxon and/or paired t-test depending on the normality of the data. X̄ : mean; SD: standard deviation; NS: not significant.
TABLE 2. Lipid Profile of Patients with T2D before and after Intake of Rosemary Tea
Before Therapy with 
Rosemary Tea 
(X−  ± SD)
At 90 Days Post-Intake 






Cholesterol (mg/dL) 204.27 ± 40.75 196.59 ± 34.04 ↓ 3.75 NS
Triglycerides (mg/dL) 198.75 ± 104.16 183.62 ± 81.39 ↓ 7.61 NS
High-density lipoproteins (mg/dL) 33.03 ± 0.88 32.71 ± 0.95 ↓ 0.96 NS
Low-density lipoproteins (mg/dL) 131.09 ± 24.54 126.54 ± 27.61 ↓ 3.46 NS
Very low-density lipoproteins (mg/dL) 170.78 ± 40.61 165.00 ± 35.14 ↓ 3.38 NS
The comparisons among baseline values (before starting the alternative therapy) and 90 days of therapy with rosemary tea were performed 
with the Wilcoxon and/or paired t-test depending on the normality of the data. X̄ : mean; SD: standard deviation; NS: not significant.
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Correlation between the Biochemical and 
Anthropometric Parameters after 90-Day Post-
Ingestion of Rosemary Tea
The analysis of the correlation coefficients 
between the anthropometric (Table 1) and bio-
chemical (Table 3) parameters indicated that insu-
lin resistance, percentage of insulin sensitivity, and 
percentage of β-cell function showed a high and 
moderate correlation with serum glucose levels 
(r = 0.813, −0.591, −0.625, respectively; P = 0.000) 
and HBA1c (r = 0.639, −0.567, −0.359, respec-
tively; P ≤ 0.001). Insulin resistance also showed a 
high correlation with cholesterol (r = 0.421; P = 
0.000), triglycerides (r  =  0.235; P = 0.038), Very 
Low-Density Lipoprotein  Cholesterol (c-VLDL) 
(r = 0.348; P = 0.002), and moderate correlations 
with MDA (r = 0.284; P = 0.012), while the per-
centage of insulin sensitivity correlated only with 
cholesterol levels (r = −0.260; P = 0.022). The 
 percentage of β-cell function with cholesterol 
TABLE 3. Percentage of Diabetic Complications in High-Risk Patients
Before Therapy 
with Rosemary Tea







Glycated hemoglobin (High risk >8.0%) 54.55% 21.88% ↓ 59.89 0.01
Glucose>130 mg/dL 75.76% 62.50% ↓ 17.50 NS
Triglycerides>150 mg/dL 66.67% 56.25% ↓ 15.62 NS
Cholesterol>200 mg/dL 54.55% 56.25% ↑ 3.11 NS
High-density lipoproteins <40 mg/dL 100% 100% -- --- NS
Low-density lipoproteins> 100 mg/dL 90.32% 83.87% ↓ 7.14 NS
Very low-density lipoproteins> 40 mg/dL 100% 100% -- --- NS



















FIG 1. Effect of Rosemary Tea Intake on Lipid Peroxidation. Differences between the different 
time periods were evaluated with a variance analysis (ANOVA) for repeated measures applying a 
Bonferroni adjustment for multiple comparisons. The comparisons were: a0 days versus 30 days; 
b0 days versus 60 days; c0 days versus 90 days; d30 days versus 60 days; e30 days versus 90 days; 
f60 days versus 90 days. P = 0.0001a,b,c.
A Shortened Treatment with Rosemary Tea
J Popul Ther Clin Pharmacol Vol 26(4):e18–e28; December 3, 2019.
This article is distributed under the terms of the Creative Commons Attribution-Non 
Commercial 4.0 International License. ©2019 Sol María Quirarte-Báez et al.
e24
(r  = −0.324; P = 0.004), c-VLDL (r = −0.325; 
P = 0.004), and MDA (r = −0.281; P = 0.013).
The Antidiabetic Drug Glibenclamide Decreased 
Total Cholesterol and LDL
Figure 2 shows the results from patients who 
received complementary therapy with pharmaco-
logical treatment, showing a statistical difference 
in the parameters of total cholesterol and LDL.
Patients with pharmacological therapy with 
glibenclamide showed a significant decrease in the 
total cholesterol concentration in relation to 
the  metformin and metformin and gliben-
clamide  groups, likewise the group that received 
glibenclamide significantly decreased the LDL con-
centration in relation to the metformin group 
(Figure 2)
DISCUSSION
In this study, we report that the ingestion of 
rosemary tea decreases some of the 
The comparisons were made using the U-Mann–Whitney test. The comparisons were: M versus G; M versus M/G; G versus M/G. 
M: metformin; G: glibenclamide; M/G: metformin and glibenclamide.
FIG 2. Effect of Pharmacological Treatment on the Parameters Evaluated in Patients under 
Complementary Therapy with Romero Tea.
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anthropometric measurements (related with the 
protective effect on fat accumulation and hyper-
trophy inhibition) and significantly reduces insu-
lin resistance, serum glucose, and lipid 
peroxidation in T2D patients from the state of 
Durango in Mexico.
As reported by the literature, it has been shown 
that rosemary leaves powder at a dose of 3 g/day 
during 4 weeks exerts a positive effect on the 
reduction of glucose levels, lipid profile, and lipid 
peroxidation.18 However, patients should ingest 
high doses of powder contained in capsules. This 
formulation constitutes the intake of 10 capsules 
per day, which should first release the active 
metabolites and then absorbed (rosemary leaf 
powder mixed with gastric juice). Herein, we 
sought to evaluate whether a shortened dose and 
time of treatment as well as pharmaceutical pre-
sentation of rosemary tea instead of powder 
could have a therapeutic effect on T2D treatment. 
The results indicated that a shortened dose, time, 
and changing the pharmaceutical presentation of 
rosemary tea (2 g/L/day) had a favorable effect on 
the different biochemical parameters measured in 
patients with T2D (Tables 1 and 2, Figure 1)
After rosemary tea intake, patients had an 
HbA1c percentage of 9.09 ± 2.72%, while post 
rosemary ingestion, it was 7.72 ± 1.82%, thus 
leading to a decrease in the percentage of patients 
who were at high risk of diabetic complications 
(HBA1c >8%) by 59.89% (Table 1). Although the 
average serum glucose levels did not decrease sta-
tistically after the intake of rosemary tea, the per-
centage of patients with glucose levels >130 mg/
dL decreased by 15.62% after rosemary tea ther-
apy (Table 2). It is highly possible that serum glu-
cose is directly related to the diet of the last 24 h, 
so that patients could present diet transgressions. 
No statistical difference was found in the lipid 
profile of patients prior and post phytopharma-
cological therapy with rosemary. However, a 
slight decrease in triglyceride (7.61%), cholesterol 
(3.75%), LDL lipoprotein (3.46%), and VLDL 
lipoprotein levels (3.38%) was observed after the 
complementary therapy with rosemary tea 
(Tables 2 and 3). The observed effects of the rose-
mary tea intake in T2D patients could be due to 
the fact that rosemary significantly reduces blood 
glucose levels16,17 and potentially increases liver 
glycolysis and fatty acid oxidation through the 
activation of cyclic adenosine monophosphate 
(cAMP) and peroxisome proliferator-activated 
receptor (PPARs) pathways.22–24 The intake of 
rosemary tea in the patients studied decreased 
waist and hip circumference, and this decrease 
could be attributed to the fact that rosemary con-
tains carnosic acid which has been reported to 
produce a protective effect on fat accumulation 
and inhibits hypertrophy of adipocytes from 
white adipose tissue conditioning the decrease of 
tissue.13,25–28 Moreover, the data reported are con-
sistent with those reported by Labban et al., and 
the authors evaluated doses of 2, 5, and 10 g of 
rosemary leaves powder in healthy individuals. 
They found that the intake of rosemary at doses 
of 2 g/day did not significantly decrease serum 
glucose and that the hypoglycemic effect of rose-
mary was dose-dependent, as the 5 and 10 g doses 
statistically decreased serum glucose levels, with 
this decrease being greater in the 10 g dose, with-
out any toxic effect.18 Moreover, Al Jamal et al. 
reported a 9% decrease in serum glucose in 
patients with T2D with dyslipidemia after ingest-
ing 3 g of rosemary leaves per day for 4 weeks and 
21% in healthy subjects.19 In addition, Yun et al. 
demonstrated that the phenolic diterpenes from 
the aqueous extract of rosemary suppress the 
responsiveness to cAMP of gluconeogenic 
genes.29 Stefanon et al. reported that rosemary 
extract modulates the differentiation of human 
adipocytes and significantly interferes with adi-
pogenesis and lipid metabolism.30
The hypolipidemic potential of rosemary 
leaves has been demonstrated by lowering blood 
levels of triglycerides, cholesterol, LDL lipopro-
tein, and increasing HDL lipoprotein in vivo.31,32
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Similarly, rosemary phenolic compounds have 
been reported to reduce blood cholesterol con-
centrations in rats with hypercholesterolemia33 
and the administration of rosemary extract 
enriched with carnosic acid improved the lipid 
profile in Zucker rats.34
Bustanji et al. reported that rosemary extract 
inhibits lipase-sensitive hormone (HSL), which 
impinges on the metabolic switch between glu-
cose and free fatty acids (FFAs)35; while rosemary 
intake significantly decreased lipoperoxidation in 
the patients studied at 30 days, maintaining this 
decrease in relation to the time of rosemary tea 
intake.
The findings described in this article show that 
insulin resistance and sensitivity as well as pan-
creatic β-cell function were significantly cor-
related with serum glucose levels and HbA1c, 
indicating that there is a decrease in 
hyperinsulinism.36
Patients with pharmacological therapy with 
metformin and complementary therapy with 
rosemary tea significantly decreased total choles-
terol and LDL levels compared to the metformin 
and metformin and glibenclamide group. It has 
been reported that glibenclamide therapy signifi-
cantly decreases the levels of serum total choles-
terol after 15 and 30 days of therapyand increases 
HDL serum levels.37 Glibenclamide promoted the 
HDL-independent cholesterol efflux by decreas-
ing esterified cholesterol and increasing the 
release of free cholesterol and secretion of apoli-
poprotein E into the medium.38
In summary, these data show that rosemary 
soluble active principles in water at a low dose 
constitute a promising treatment for T2D and 
resistant T2D patients.
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